Table 1.
Monoclonal antibody-based trials for oral cancers
| Product name | Sponsor | Target | Estimated date of completion | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
| Cemiplimab | ISA Pharmaceuticals | PD-1 | November 2024 | II | Recruiting | NCT04398524 |
| Bevacizumab | National Cancer Institute (NCI) | VEGF-A | March 2010 | I | Completed | NCT02002182 |
| Anti-EGFR monoclonal antibody | Fudan University | EGFR | December 2020 | II | Recruiting | NCT04508829 |
| Nivolumab | Medical University of South Carolina | PD-1 | November 2021 | I/II | Completed | NCT03021993 |
| Cetuximab | Eastern Cooperative Oncology Group | EGFR | April 2004 | III | Completed | NCT00003809 |
| Sintilimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PD-1 | October 2027 | II | Not yet recruiting | NCT05000892 |
| Toripalimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PD-1 | June 2027 | II | Not yet recruiting | NCT04825938 |
| Anti-OX40 antibody | Providence Health & Services | OX40 | October 2022 | I | Active, not recruiting | NCT02274155 |
| Bevacizumab | M.D. Anderson Cancer Center | VEGF | March 2022 | I | Active, not recruiting | NCT01552434 |
PD-1 Programmed cell death-1; VEGF-A Vascular endothelial growth factor A; EGFR Endothelial growth factor receptor; OX40 (CD134) A member of the tumor necrosis factor family of receptors